1
PMHNP NUR6501 FINAL EXAM FULL PACKAGE QUESTIONS
ANSWERS AND RATIONALES 2026-27 LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
The PMHNP NUR6501 Final Exam is the comprehensive summative assessment
for the Advanced Psychiatric Mental Health Care of Adults and Older Adults
course, a cornerstone of Psychiatric-Mental Health Nurse Practitioner
education. This 10-week graduate-level course provides an in-depth
exploration of psychiatric care for adults and older adults, focusing on the
assessment, diagnosis, and management of mood, anxiety, neurocognitive, and
substance use disorders. The final exam evaluates clinical decision-making,
psychopharmacology, differential diagnosis, therapeutic modalities, and ethical
practice across the lifespan. The PMHNP certification examination itself is an
entry-level competency-based exam that tests clinical knowledge across the life
span, structured around four core domains: Assess, Diagnose, Plan, and
Evaluate. This question bank provides 200 advanced, scenario-based multiple-
choice questions that mirror the difficulty and clinical reasoning required on
the actual NUR6501 final exam and the national certification examination. Each
question is accompanied by a detailed rationale explaining why the correct
answer is right and why the distractors are wrong. By working through these
high-yield questions, candidates will sharpen their diagnostic reasoning,
psychopharmacologic decision-making, and ethical judgment—maximizing
their chances of passing on the first attempt.
CORE DOMAINS TESTED
• Scientific Foundations: Neuroanatomy, neurophysiology,
pathophysiology, epidemiology of psychiatric disorders, psychiatric and
medical comorbidities, growth and development, and research
methodology.
• Pharmacology and Psychopharmacology: Pharmacologic therapies,
pharmacodynamics and pharmacokinetics, psychopharmacology,
interactions between classes of medication, medication monitoring,
polypharmacy, and pharmacogenetic testing.
,2
• Advanced Practice Skills: Psychiatric assessment, clinical interviewing,
components of a psychiatric evaluation, mental status examination,
screening and assessment instruments, diagnostic and laboratory tests,
differential diagnosis, and diagnostic decision-making using DSM-5-TR.
• Diagnosis and Treatment: DSM-5-TR criteria for mood disorders, anxiety
disorders, psychotic disorders, personality disorders, neurocognitive
disorders, substance use disorders, and treatment planning with both
pharmacological and non-pharmacological interventions.
• Psychotherapy and Related Theories: Psychotherapeutic foundations,
individual psychotherapy theories and methods, group psychotherapy
theories, family psychotherapy theories, theories of change, and
therapeutic communication.
• Ethical, Legal, and Cultural Care: Scope and standards of practice,
informed consent, confidentiality, mandatory reporting, duty to warn,
involuntary commitment, professional boundaries, cultural awareness
and humility, and social determinants of health.
• Crisis Intervention and Safety: Risk assessment and safety planning,
harm reduction, crisis management and de-escalation techniques, least
restrictive interventions, trauma-informed care, and suicide prevention.
• Geriatric and Adult Psychiatry: Late-life depression, dementia, delirium,
polypharmacy in older adults, caregiver support, and age-appropriate
care practices.
,3
QUESTIONS 1-200
Q1: A 42-year-old male with treatment-resistant schizophrenia has
been stable on clozapine for 8 months. He presents to the clinic with
fever, sore throat, and malaise. His absolute neutrophil count is
1,200/µL. What is the priority action?
A) Continue clozapine and recheck ANC in 1 week
B) Hold clozapine and obtain an urgent hematology consult
C) Reduce clozapine dose by 50% and monitor weekly
D) Add lithium to stimulate neutrophil production
B) Hold clozapine and obtain an urgent hematology consult
Rationale: The correct answer is B. An ANC of 1,200/µL indicates
moderate neutropenia (normal ANC > 1,500/µL), which requires
holding clozapine and urgent hematologic evaluation because
clozapine carries a black box warning for severe neutropenia and
agranulocytosis. Option A is incorrect because continuing clozapine
with an already low ANC risks progression to agranulocytosis. Option
C is incorrect because dose reduction does not mitigate the
hematologic risk. Option D is incorrect because lithium is not a
standard treatment for clozapine-induced neutropenia and would
add unnecessary risk.
Q2: A 28-year-old female with major depressive disorder is started on
fluoxetine 20 mg daily. She returns after 4 weeks reporting no
improvement. She has no suicidal ideation. What is the most
appropriate next step?
A) Switch to a different SSRI
B) Increase fluoxetine to 40 mg daily
C) Add bupropion for augmentation
D) Discontinue fluoxetine and start venlafaxine
B) Increase fluoxetine to 40 mg daily
Rationale: The correct answer is B. The patient has had an adequate
, 4
trial duration (4 weeks) but has not yet reached the optimal dose.
Guidelines recommend optimizing the dose of the current
antidepressant before switching or augmenting. Option A is
premature because the current medication has not been optimized.
Option C is an augmentation strategy reserved for partial response or
after failed adequate trials. Option D is also premature and would
expose the patient to a new medication without first optimizing the
current one.
Q3: A 67-year-old male with Alzheimer's disease is started on
donepezil 5 mg daily. His wife reports he has developed nausea and
diarrhea. What is the most appropriate management?
A) Discontinue donepezil immediately
B) Administer the dose at bedtime with food
C) Increase the dose to 10 mg for better efficacy
D) Add ondansetron for nausea
B) Administer the dose at bedtime with food
Rationale: The correct answer is B. GI side effects are common with
cholinesterase inhibitors and can often be managed by taking the
medication at bedtime with food to reduce daytime symptoms.
Option A is incorrect because GI side effects are usually transient and
dose-related, not a reason for immediate discontinuation. Option C is
incorrect because increasing the dose would likely worsen GI
symptoms. Option D is incorrect because adding an antiemetic does
not address the underlying issue and may cause additional side
effects.
Q4: A 35-year-old female with bipolar I disorder is currently in a
manic episode with psychotic features. She is not sleeping, is verbally
aggressive, and has stopped taking her lithium 2 weeks ago. Which
medication is most appropriate for acute stabilization?
A) Lamotrigine
PMHNP NUR6501 FINAL EXAM FULL PACKAGE QUESTIONS
ANSWERS AND RATIONALES 2026-27 LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
The PMHNP NUR6501 Final Exam is the comprehensive summative assessment
for the Advanced Psychiatric Mental Health Care of Adults and Older Adults
course, a cornerstone of Psychiatric-Mental Health Nurse Practitioner
education. This 10-week graduate-level course provides an in-depth
exploration of psychiatric care for adults and older adults, focusing on the
assessment, diagnosis, and management of mood, anxiety, neurocognitive, and
substance use disorders. The final exam evaluates clinical decision-making,
psychopharmacology, differential diagnosis, therapeutic modalities, and ethical
practice across the lifespan. The PMHNP certification examination itself is an
entry-level competency-based exam that tests clinical knowledge across the life
span, structured around four core domains: Assess, Diagnose, Plan, and
Evaluate. This question bank provides 200 advanced, scenario-based multiple-
choice questions that mirror the difficulty and clinical reasoning required on
the actual NUR6501 final exam and the national certification examination. Each
question is accompanied by a detailed rationale explaining why the correct
answer is right and why the distractors are wrong. By working through these
high-yield questions, candidates will sharpen their diagnostic reasoning,
psychopharmacologic decision-making, and ethical judgment—maximizing
their chances of passing on the first attempt.
CORE DOMAINS TESTED
• Scientific Foundations: Neuroanatomy, neurophysiology,
pathophysiology, epidemiology of psychiatric disorders, psychiatric and
medical comorbidities, growth and development, and research
methodology.
• Pharmacology and Psychopharmacology: Pharmacologic therapies,
pharmacodynamics and pharmacokinetics, psychopharmacology,
interactions between classes of medication, medication monitoring,
polypharmacy, and pharmacogenetic testing.
,2
• Advanced Practice Skills: Psychiatric assessment, clinical interviewing,
components of a psychiatric evaluation, mental status examination,
screening and assessment instruments, diagnostic and laboratory tests,
differential diagnosis, and diagnostic decision-making using DSM-5-TR.
• Diagnosis and Treatment: DSM-5-TR criteria for mood disorders, anxiety
disorders, psychotic disorders, personality disorders, neurocognitive
disorders, substance use disorders, and treatment planning with both
pharmacological and non-pharmacological interventions.
• Psychotherapy and Related Theories: Psychotherapeutic foundations,
individual psychotherapy theories and methods, group psychotherapy
theories, family psychotherapy theories, theories of change, and
therapeutic communication.
• Ethical, Legal, and Cultural Care: Scope and standards of practice,
informed consent, confidentiality, mandatory reporting, duty to warn,
involuntary commitment, professional boundaries, cultural awareness
and humility, and social determinants of health.
• Crisis Intervention and Safety: Risk assessment and safety planning,
harm reduction, crisis management and de-escalation techniques, least
restrictive interventions, trauma-informed care, and suicide prevention.
• Geriatric and Adult Psychiatry: Late-life depression, dementia, delirium,
polypharmacy in older adults, caregiver support, and age-appropriate
care practices.
,3
QUESTIONS 1-200
Q1: A 42-year-old male with treatment-resistant schizophrenia has
been stable on clozapine for 8 months. He presents to the clinic with
fever, sore throat, and malaise. His absolute neutrophil count is
1,200/µL. What is the priority action?
A) Continue clozapine and recheck ANC in 1 week
B) Hold clozapine and obtain an urgent hematology consult
C) Reduce clozapine dose by 50% and monitor weekly
D) Add lithium to stimulate neutrophil production
B) Hold clozapine and obtain an urgent hematology consult
Rationale: The correct answer is B. An ANC of 1,200/µL indicates
moderate neutropenia (normal ANC > 1,500/µL), which requires
holding clozapine and urgent hematologic evaluation because
clozapine carries a black box warning for severe neutropenia and
agranulocytosis. Option A is incorrect because continuing clozapine
with an already low ANC risks progression to agranulocytosis. Option
C is incorrect because dose reduction does not mitigate the
hematologic risk. Option D is incorrect because lithium is not a
standard treatment for clozapine-induced neutropenia and would
add unnecessary risk.
Q2: A 28-year-old female with major depressive disorder is started on
fluoxetine 20 mg daily. She returns after 4 weeks reporting no
improvement. She has no suicidal ideation. What is the most
appropriate next step?
A) Switch to a different SSRI
B) Increase fluoxetine to 40 mg daily
C) Add bupropion for augmentation
D) Discontinue fluoxetine and start venlafaxine
B) Increase fluoxetine to 40 mg daily
Rationale: The correct answer is B. The patient has had an adequate
, 4
trial duration (4 weeks) but has not yet reached the optimal dose.
Guidelines recommend optimizing the dose of the current
antidepressant before switching or augmenting. Option A is
premature because the current medication has not been optimized.
Option C is an augmentation strategy reserved for partial response or
after failed adequate trials. Option D is also premature and would
expose the patient to a new medication without first optimizing the
current one.
Q3: A 67-year-old male with Alzheimer's disease is started on
donepezil 5 mg daily. His wife reports he has developed nausea and
diarrhea. What is the most appropriate management?
A) Discontinue donepezil immediately
B) Administer the dose at bedtime with food
C) Increase the dose to 10 mg for better efficacy
D) Add ondansetron for nausea
B) Administer the dose at bedtime with food
Rationale: The correct answer is B. GI side effects are common with
cholinesterase inhibitors and can often be managed by taking the
medication at bedtime with food to reduce daytime symptoms.
Option A is incorrect because GI side effects are usually transient and
dose-related, not a reason for immediate discontinuation. Option C is
incorrect because increasing the dose would likely worsen GI
symptoms. Option D is incorrect because adding an antiemetic does
not address the underlying issue and may cause additional side
effects.
Q4: A 35-year-old female with bipolar I disorder is currently in a
manic episode with psychotic features. She is not sleeping, is verbally
aggressive, and has stopped taking her lithium 2 weeks ago. Which
medication is most appropriate for acute stabilization?
A) Lamotrigine
